Precision Dosing of Antibody Therapeutics: PET Imaging for Quantifying Activity in Tumors

Explore novel concepts in quantifying therapeutic antibody activity in tumors through PET imaging in this 25-minute lecture from Johns Hopkins Medicine. Delve into the success of anti-cancer therapies, comparing drug-centric and target-centric approaches. Discover how antibodies can be used as imaging agents and learn about quantifying target pharmacodynamics at disease sites. Examine a pharmacodynamics approach to measure antibody activity, focusing on Programmed Death Ligand 1 (PD-L1) as a target for immune checkpoint blockade imaging. Investigate PD-L1 imaging agents with improved image contrast, such as [18F]DK222. Gain insights into dose finding and optimization of antibody therapeutics, including the quantification of accessible PD-L1 levels at tumors for more precise dosing strategies.

Intro
Success of Anti-cancer Therapies
Drug-centric Approach Antibodies as imaging agents
Target-centric Approach Quantify target pharmacodynamics at the disease site
A Pharmacodynamics Approach to Quantify Antibody Activity at the Disease Site Measuring the target instead of the drug
Programmed Death Ligand 1 (PD-L1) A target for imaging immune checkpoint blockade
PD-L1 Imaging Agents with Improved Image Contrast [18F]DK222
Dose Finding and Optimization of Antibody Therapeutics
Quantification of Accessible PD-L1 Levels at the Tumor for dose finding and dose optimization